New Jersey is currently home to 1652 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
NCT02675829
Recruiting
The purpose of this study is to find out what effects, a drug called ado-trastuzumab emtansine has on the patient and their cancer which is thought to be controlled by the abnormal HER2 gene.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Solid Tumor Cancers, Lung Cancer, Bladder Cancer, Urinary Tract Cancers
Register for Updates
R3THA Rehabilitation Feasibility and Usability Study
NCT06854978
Recruiting
The purpose of this study is to assess how the Rehabilitation Technologies for Hand and Arm (R3THA) device can be used for rehabilitation of people with stroke. the study will evaluate the feasibility of R3THA as outpatient telerehabilitation administered by trained clinicians to individuals with stroke.
Gender:
ALL
Ages:
Between 20 years and 80 years
Trial Updated:
02/28/2025
Locations: Kessler Foundation, West Orange, New Jersey
Conditions: Stroke
Register for Updates
A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03.
NCT06780306
Recruiting
The purpose of this randomized, controlled, multicenter study is to evaluate the safety and efficacy of TTAX03 in participants with mild to moderate DED. The primary question it aims to answer is if TTAX03 is safe. The secondary is the effectiveness. Researchers will compare 10mg of TTAX03 reconstituted in 150, 300, or 600 uL saline to the saline control group to look at effectiveness. Participants will be randomized to a treatment group one time and be evaluated at 5 different study visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Eye Associates of North Jersey, Dover, New Jersey
Conditions: Dry Eye, Dry Eye Disease (DED), Dry Eye Disease With Severe Keratitis
Register for Updates
Integrity Implant System Post Market Clinical Follow-Up Study
NCT06741527
Recruiting
The study design is a prospective, multi-center, single-arm, non-randomized post market clinical follow-up study to confirm the performance, safety and clinical benefit of the Integrity Implant System when used for rotator cuff tear augmentation (with or without repair).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Virtua Health, Marlton, New Jersey
Conditions: Rotator Cuff Tears of the Shoulder
Register for Updates
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
NCT06532032
Recruiting
The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and docetaxel combination therapy in participants with metastatic non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected RP2CD in participants with NSCLC without oncogenic driver mutations with disease progression on platinum-based chemotherapy and immune checkpoint inhibitor, in the Phase 2 (ex... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Hunterdon Hematology Oncology, Flemington, New Jersey
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
Gender:
ALL
Ages:
All
Trial Updated:
02/28/2025
Locations: Jersey Shore University Medical Center, Neptune, New Jersey
Conditions: H3 K27M, Glioma
Register for Updates
Innovations in Genicular Outcomes Registry
NCT05495334
Recruiting
The registry will capture prospective data on patients receiving pain management for chronic pain due to knee osteoarthritis (OA) or pain optimization for knee arthroplasty due to knee OA. The OA pain therapies may include cryo nerve block, radiofrequency ablation (RFA), intra-articular (IA) corticosteroids, viscosupplementation, opioids, and others (e.g., non-steroidal anti-inflammatory drugs \[NSAIDs\]).
Gender:
ALL
Ages:
All
Trial Updated:
02/28/2025
Locations: Jersey City Medical Center, Jersey City, New Jersey
Conditions: Knee Osteoarthritis
Register for Updates
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
NCT05371613
Recruiting
This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT) for mucopolysaccharidosis type II (MPS II). Participants may also qualify to enter an open-label treatment phase with DNL310 or idursulfase based on pre-specified criteria.
Gender:
ALL
Ages:
Between 2 years and 26 years
Trial Updated:
02/28/2025
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Mucopolysaccharidosis II
Register for Updates
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05147220
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/28/2025
Locations: Jersey Shore University Medical Ctr, Neptune, New Jersey
Conditions: Relapsing Multiple Sclerosis
Register for Updates
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738
Recruiting
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Research Site, Camden, New Jersey
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
NCT06657768
Recruiting
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 29 weeks for Par... Read More
Gender:
ALL
Ages:
Between 45 years and 85 years
Trial Updated:
02/27/2025
Locations: CenExel-HRI, Marlton, New Jersey
Conditions: Alzheimer Disease, Healthy
Register for Updates
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The study will last about 18 months
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Circuit Clinical/Mercer Allergy and Pulmonary Associates, Hamilton, New Jersey
Conditions: Perennial Allergic Rhinitis (PAR)
Register for Updates